Anti-VEGF therapy has recently been approved by the FDA to prevent the progression of retinopathy of prematurity (ROP; a leading cause of childhood blindness) and preserve vision in preterm newborns. Following injection, it is known that these drugs leave the eye and enter the systemic circulation; however, from there, the distribution of these drugs to the developing organs is unknown. Whilst...
The corneal epithelium is a self-renewing tissue maintained with remarkable precision. Its regeneration is driven by limbal epithelial stem cells (LESCs), which reside at the corneal periphery and give rise to transit amplifying cells (TACs) that migrate centripetally toward the centre. These TACs continually replenish the tissue and, together with vertical delamination between layers, sustain...
Wet age-related macular degeneration is a chronic ocular disease treated by repeated intravitreal injections. The relatively short intravitreal half-life of these therapeutics leads to frequent administration, creating a substantial treatment burden. Accurate estimation of the effective diffusion coefficient is central to predicting intravitreal half-life and to the rational design of...
Age-related macular degeneration (AMD) is a primary cause of irreversible vision loss worldwide, causing years of progressive visual decline and reduced quality of life that may culminate in severe visual impairment or blindness. Available therapeutic options are limited to late-stage disease, when irreversible damage to ocular tissues has already occurred and patients experience significant...
Vision loss and ocular disease constitute major global health challenges. In recent years, mathematical ophthalmology has experienced substantial growth and increasing acceptance within the clinical and biomedical communities, driven by advances in ocular imaging, experimental measurement, and the availability of high-quality clinical and preclinical data.
This mini-symposium will highlight...
